129 related articles for article (PubMed ID: 16966683)
1. Reaching first base in the treatment of metastatic melanoma.
Eggermont AM
J Clin Oncol; 2006 Oct; 24(29):4673-4. PubMed ID: 16966683
[No Abstract] [Full Text] [Related]
2. The systemic treatment of advanced cutaneous melanoma.
Logan TF
Facial Plast Surg Clin North Am; 2003 Feb; 11(1):75-85. PubMed ID: 15062290
[No Abstract] [Full Text] [Related]
3. Oblimersen in the treatment of metastatic melanoma.
Tarhini AA; Kirkwood JM
Future Oncol; 2007 Jun; 3(3):263-71. PubMed ID: 17547520
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
[TBL] [Abstract][Full Text] [Related]
5. Randomized trials in melanoma: an update.
Eggermont AM
Surg Oncol Clin N Am; 2006 Apr; 15(2):439-51. PubMed ID: 16632225
[TBL] [Abstract][Full Text] [Related]
6. Individualized therapy of disseminated cancer using malignant melanoma as a model.
Hauschild A; Egberts F; Russo P; Kähler KC
Cancer Metastasis Rev; 2006 Jun; 25(2):253-6. PubMed ID: 16770537
[TBL] [Abstract][Full Text] [Related]
7. Genasense: it ain't over till the fat lady sings.
Stein CA
Oligonucleotides; 2007; 17(4):345-8. PubMed ID: 17949263
[No Abstract] [Full Text] [Related]
8. When will melanoma vaccines be proven effective?
Sosman JA; Weeraratna AT; Sondak VK
J Clin Oncol; 2004 Feb; 22(3):387-9. PubMed ID: 14691126
[No Abstract] [Full Text] [Related]
9. Molecular classification of patients with malignant melanoma for new therapeutic strategies.
Palmieri G; Casula M; Ascierto PA; Tanda F; Cossu A
J Clin Oncol; 2007 Jun; 25(16):e20-1. PubMed ID: 17538155
[No Abstract] [Full Text] [Related]
10. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
[TBL] [Abstract][Full Text] [Related]
11. FDA approves new treatment of metastatic melanoma.
Printz C
Cancer; 2016 Apr; 122(8):1149. PubMed ID: 27061518
[No Abstract] [Full Text] [Related]
12. Melanoma update.
Franz R
Dermatol Nurs; 2001 Feb; 13(1):62-3. PubMed ID: 11917302
[No Abstract] [Full Text] [Related]
13. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of disseminated malignant melanoma].
Steiner M; Robinson E
Harefuah; 1975 Feb; 88(4):163-7. PubMed ID: 1123195
[No Abstract] [Full Text] [Related]
15. Melanoma vaccines: possible progress after years of frustration?
Schmidt C
J Natl Cancer Inst; 2009 Feb; 101(3):140-1. PubMed ID: 19176461
[No Abstract] [Full Text] [Related]
16. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
; Celis E
Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
18. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
Agarwala SS; Keilholz U; Gilles E; Bedikian AY; Wu J; Kay R; Stein CA; Itri LM; Suciu S; Eggermont AM
Eur J Cancer; 2009 Jul; 45(10):1807-14. PubMed ID: 19419855
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in melanoma outcome and survival.
Le TT; Pitman KT
Facial Plast Surg Clin North Am; 2003 Feb; 11(1):33-41. PubMed ID: 15062285
[No Abstract] [Full Text] [Related]
20. Melanoma and immunotherapy.
Eggermont AM; Schadendorf D
Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
